How big is the Transthyretin Amyloidosis Treatment Market?

The Transthyretin Amyloidosis Treatment Market size is expected to reach USD 5.30 billion in 2024 and grow at a CAGR of 15.40% to reach USD 10.90 billion by 2029. Read More

What is the current Transthyretin Amyloidosis Treatment Market size?

In 2024, the Transthyretin Amyloidosis Treatment Market size is expected to reach USD 5.30 billion. Read More

Who are the key players in Transthyretin Amyloidosis Treatment Market?

Pfizer Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Inc., BridgeBio Inc and Intellia Therapeutics, Inc. are the major companies operating in the Transthyretin Amyloidosis Treatment Market. Read More

Which is the fastest growing region in Transthyretin Amyloidosis Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Transthyretin Amyloidosis Treatment Market?

In 2024, the North America accounts for the largest market share in Transthyretin Amyloidosis Treatment Market. Read More

What years does this Transthyretin Amyloidosis Treatment Market cover, and what was the market size in 2023?

In 2023, the Transthyretin Amyloidosis Treatment Market size was estimated at USD 4.48 billion. The report covers the Transthyretin Amyloidosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Transthyretin Amyloidosis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Transthyretin Amyloidosis Treatment Companies

This report lists the top Transthyretin Amyloidosis Treatment companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Transthyretin Amyloidosis Treatment industry.